drugset / Trial / NCT00566397
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.
Timeline
- Start
- 2007-12
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Met primary endpoint
release “primary endpoint, ADAS-cog11, and relative sensitivity analyses showed statistically significant benefit at month 18” vtvtherapeutics.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azeliragon | Small molecule | 5 mg | — |
| Subject | Azeliragon | Small molecule | 20 mg | — |